Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses
暂无分享,去创建一个
L. Valiquette | E. Tsakonas | C. Perras | K. Farrah | J. Conly | S. Ndegwa
[1] Kumanan Wilson,et al. The effect of hospital-acquired Clostridium difficile infection on in-hospital mortality. , 2010, Archives of internal medicine.
[2] Mark A. Miller,et al. Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection , 2010, Infection Control & Hospital Epidemiology.
[3] D R Lairson,et al. Economic healthcare costs of Clostridium difficile infection: a systematic review. , 2010, The Journal of hospital infection.
[4] L. Miller,et al. Dose–Response Efficacy of a Proprietary Probiotic Formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for Antibiotic-Associated Diarrhea and Clostridium difficile-Associated Diarrhea Prophylaxis in Adult Patients , 2010, The American Journal of Gastroenterology.
[5] E. Kuijper,et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[6] O. Dekkers,et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[7] D. Lieu. Oral vancomycin 6-week taper regimen, as treatment for both initial and recurrent disease, reduces relapse of Clostridium difficile infection (CDI) , 2009 .
[8] D. Gravel. Reply to Bayardelle , 2009 .
[9] Mark H. Wilcox,et al. Clostridium difficile infection: new developments in epidemiology and pathogenesis , 2009, Nature Reviews Microbiology.
[10] A. Guyot,et al. Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. , 2009, The Journal of hospital infection.
[11] Stuart Johnson. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. , 2009, The Journal of infection.
[12] D. Gerding,et al. Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. , 2009, Gastroenterology.
[13] E. Kuijper,et al. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[14] D. Leffler,et al. Treatment of Clostridium difficile-associated disease. , 2009, Gastroenterology.
[15] M. Hu,et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. , 2009, Gastroenterology.
[16] P. Malani,et al. Clostridium Difficile Infection in the “Oldest” Old: Clinical Outcomes in Patients Aged 80 and Older , 2009, Journal of the American Geriatrics Society.
[17] J. Sanderson,et al. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. , 2009, The Lancet. Infectious diseases.
[18] L. Johnston,et al. Hospital infection control strategies for vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clostridium difficile , 2009, Canadian Medical Association Journal.
[19] C. Seder,et al. Early colectomy may be associated with improved survival in fulminant Clostridium difficile colitis: an 8-year experience. , 2009, American journal of surgery.
[20] N. McFadden,et al. Risk Factors for Mortality Following Emergency Colectomy for Fulminant Clostridium difficile Infection , 2009, Diseases of the colon and rectum.
[21] Mark Miller,et al. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Kelly Karpa,et al. Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent episodes? , 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.
[23] L. Mcfarland. Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies , 2009, Current opinion in gastroenterology.
[24] C. Donskey,et al. Skin and Environmental Contamination With Vancomycin-Resistant Enterococci in Patients Receiving Oral Metronidazole or Oral Vancomycin Treatment for Clostridium difficile–Associated Disease , 2009, Infection Control & Hospital Epidemiology.
[25] K. Garey,et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.
[26] I. Critchley,et al. New agents for Clostridium difficile-associated disease , 2008, Expert opinion on investigational drugs.
[27] A. Barkun,et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection , 2008, Canadian Medical Association Journal.
[28] J. Caeiro,et al. New advances in Clostridium difficile infection: changing epidemiology, diagnosis, treatment and control , 2008, Current opinion in infectious diseases.
[29] D. Farver,et al. New advances in the treatment of Clostridium difficile infection (CDI) , 2008, Therapeutics and clinical risk management.
[30] P. Gastmeier,et al. Costs of nosocomial Clostridium difficile-associated diarrhoea. , 2008, The Journal of hospital infection.
[31] C. Donskey,et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] T. Louie,et al. Clostridium difficile Infections in a Canadian Tertiary Care Hospital before and during a Regional Epidemic Associated with the BI/NAP1/027 Strain , 2008, Antimicrobial Agents and Chemotherapy.
[33] J. Pépin. Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic? , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] E. Kuipers,et al. Clostridium difficile infection , 2008, The Lancet.
[35] S. Chasan-Taber,et al. Results of a phase Iii trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea , 2008 .
[36] A. Duffy,et al. Defining Surgical Therapy for Pseudomembranous Colitis With Toxic Megacolon , 2008, Journal of clinical gastroenterology.
[37] C. Donskey,et al. Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease , 2008, Antimicrobial Agents and Chemotherapy.
[38] J. Halsey. Current and future treatment modalities for Clostridium difficile-associated disease. , 2008, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[39] David Moher,et al. Assessing the Quality of Reports of Systematic Reviews: The QUOROM Statement Compared to Other Tools , 2008 .
[40] T. Monaghan,et al. Recent advances in Clostridium difficile-associated disease , 2008, Postgraduate Medical Journal.
[41] R. Nelson,et al. Probiotics for treatment of Clostridium difficile-associated colitis in adults. , 2008, The Cochrane database of systematic reviews.
[42] Carlene A. Muto,et al. Measures to control and prevent Clostridium difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[43] B. Fireman,et al. Case-Control Study of Antibiotic Use and Subsequent Clostridium difficile–Associated Diarrhea in Hospitalized Patients , 2008, Infection Control & Hospital Epidemiology.
[44] L. Valiquette,et al. Outcomes of Clostridium difficile-Associated Disease Treated With Metronidazole or Vancomycin Before and After the Emergence of NAP1/027 , 2007, The American Journal of Gastroenterology.
[45] G. Raugi,et al. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] A. Robicsek,et al. Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] Mark Nuijten,et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[48] B. Jackson,et al. A Cost Comparison of Metronidazole and Vancomycin in the Treatment of Clostridium Difficile Associated Diarrhea: 417 , 2007 .
[49] Melinda B Davis,et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] M. Olsen,et al. Evaluation of Clostridium difficile-associated disease pressure as a risk factor for C difficile-associated disease. , 2007, Archives of internal medicine.
[51] A. Akhtar,et al. Increasing incidence of clostridium difficile-associated diarrhea in African-American and Hispanic patients: association with the use of proton pump inhibitor therapy. , 2007, Journal of the National Medical Association.
[52] M. Dionne,et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[53] Bette Jensen,et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. , 2006, Archives of internal medicine.
[54] D. Juurlink,et al. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[55] E. Bouza,et al. Antimicrobial therapy of Clostridium difficile-associated diarrhea. , 2006, The Medical clinics of North America.
[56] S. Suissa,et al. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy , 2006, Canadian Medical Association Journal.
[57] L. Mcfarland. Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease , 2006, The American Journal of Gastroenterology.
[58] Ken Dewar,et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.
[59] L. Eggertson. C. difficile may have killed 2000 in Quebec: study , 2005, Canadian Medical Association Journal.
[60] L. Valiquette,et al. Mortality attributable to nosocomial Clostridium difficile–associated disease during an epidemic caused by a hypervirulent strain in Quebec , 2005, Canadian Medical Association Journal.
[61] V. Morinville,et al. Clostridium difficile-associated diarrhea in 200 Canadian children. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[62] F. Friedenberg,et al. Clostridium difficile Among Hospitalized Patients Receiving Antibiotics A Case-Control Study , 2005, Infection Control & Hospital Epidemiology.
[63] J. Brophy,et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: a systematic review , 2005, Canadian Medical Association Journal.
[64] J. Pépin,et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] D. Musher,et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] G. Wolf-Klein,et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. , 2005, Journal of the American Medical Directors Association.
[67] Carlene A. Muto,et al. A Large Outbreak of Clostridium difficile–Associated Disease with an Unexpected Proportion of Deaths and Colectomies at a Teaching Hospital Following Increased Fluoroquinolone Use , 2005, Infection Control & Hospital Epidemiology.
[68] P. Beck,et al. Clostridium difficile-associated colitis. , 2004, Canadian family physician Medecin de famille canadien.
[69] Louis Valiquette,et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.
[70] J. Pépin,et al. Clostridium difficile infection in hospitals: a brewing storm , 2004, Canadian Medical Association Journal.
[71] F. Friedenberg,et al. Factors Associated With Failure of Metronidazole in Clostridium difficile–associated Disease , 2004, Journal of clinical gastroenterology.
[72] T. Karasawa,et al. Clostridium difficile colonization in healthy adults: transient colonization and correlation with enterococcal colonization. , 2004, Journal of medical microbiology.
[73] F. Friedenberg,et al. Predicting failure of metronidazole therapy in patients with Clostridium difficile-associated diarrhea , 2003 .
[74] A. Glatt,et al. Effectiveness and appropriateness of empiric metronidazole for Clostridium difficile-associated diarrhea. , 2003 .
[75] S. Malnick,et al. Treatment of Clostridium Difficile-Associated Diarrhea , 2002, The Annals of pharmacotherapy.
[76] Ron Goeree,et al. Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.
[77] Lynne V McFarland,et al. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease , 2002, American Journal of Gastroenterology.
[78] T. Peláez,et al. Reassessment of Clostridium difficile Susceptibility to Metronidazole and Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.
[79] Mark A. Miller,et al. Morbidity, Mortality, and Healthcare Burden of Nosocomial Clostridium Difficile-Associated Diarrhea in Canadian Hospitals , 2002, Infection Control & Hospital Epidemiology.
[80] F. Barbut,et al. Epidemiology of Recurrences or Reinfections ofClostridium difficile-Associated Diarrhea , 2000, Journal of Clinical Microbiology.
[81] Kearney,et al. Clostridium difficile‐associated diarrhoea in hospitalised patients , 2000, Journal of clinical pharmacy and therapeutics.
[82] D. Yadav,et al. Clostridium difficile colitis: factors influencing treatment failure and relapse—a prospective evaluation , 1998, American Journal of Gastroenterology.
[83] N. Black,et al. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. , 1998, Journal of epidemiology and community health.
[84] B. Wiggs,et al. Recent trends in diagnosis and treatment of Clostridium difficile in a tertiary care facility. , 1998, American journal of surgery.
[85] M. Wilcox,et al. Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection? , 1998, The Journal of hospital infection.
[86] L. Sutherland,et al. Review article: treatment of Clostridium difficile infection , 1997, Alimentary pharmacology & therapeutics.
[87] R. Fekety. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. , 1997, The American journal of gastroenterology.
[88] C. Surawicz,et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] M. Wilcox,et al. Financial burden of hospital-acquired Clostridium difficile infection. , 1996, The Journal of hospital infection.
[90] T O Jefferson,et al. Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.
[91] T. Riley. Antibiotic-Associated Diarrhoea , 1996, PharmacoEconomics.
[92] W. Graninger,et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[93] M. Wilcox,et al. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. , 1995, The Journal of antimicrobial chemotherapy.
[94] L. Peterson,et al. Clostridium Difficile-Associated Diarrhea and Colitis , 1995, Infection Control & Hospital Epidemiology.
[95] A. Vernava,et al. Patterns and prognosis ofClostridium difficile colitis , 1994, Diseases of the colon and rectum.
[96] D. Gerding,et al. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. , 1994 .
[97] R. Beart,et al. Changing epidemiology, diagnosis, and treatment of Clostridium difficile toxin‐associated colitis , 1986, The British journal of surgery.
[98] J. Bartlett. Treatment of Clostridium difficile colitis. , 1985, Gastroenterology.
[99] J. Welch,et al. Clostridium difficile colitis in surgical patients. , 1984, American journal of surgery.
[100] D. Gerding,et al. PROSPECTIVE RANDOMISED TRIAL OF METRONIDAZOLE VERSUS VANCOMYCIN FOR CLOSTRIDIUM-DIFFICILE-ASSOCIATED DIARRHOEA AND COLITIS , 1983, The Lancet.
[101] Allison Himmel,et al. Management of Clostridium difficile Infection , 2020, Chalk Talks in Internal Medicine.
[102] Guang-xi Li,et al. Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America(SHEA)and the Infectious Diseases Society of America(IDSA) , 2011 .
[103] L. Mcfarland. Update on the changing epidemiology of Clostridium difficile-associated disease , 2008, Nature Clinical Practice Gastroenterology &Hepatology.
[104] C. Suankratay,et al. A study of Clostridium difficile-associated disease at King Chulalongkorn Memorial Hospital, Thailand. , 2008, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.